Jubilant Ingrevia posted robust Q2 FY2026 results, reporting consolidated revenue of ₹11.21 billion and a 17.7% rise in net profit to ₹694.7 million. The EBITDA margin also improved, reflecting operational efficiency amidst a competitive specialty chemicals market.
Jubilant Ingrevia Q2 FY2026 Financial Performance
Jubilant Ingrevia Limited delivered a strong financial performance for the quarter ended September 30, 2025, with consolidated revenue reaching ₹11.21 billion, up 7.3% year-on-year. The company’s net profit rose impressively by 17.7% to ₹694.7 million compared to the same quarter last year.
EBITDA increased by 8.9% to ₹1.35 billion, with an improved EBITDA margin of 12.09%, up 17 basis points year-on-year, highlighting improved cost management and operational efficiency. These results reflect the company’s focus on specialty chemicals and nutritional products, which continue to drive growth amid evolving market demand.
The management also reaffirmed its commitment to sustainability and operational excellence, with ongoing initiatives to optimize costs and deploy renewable energy sources in manufacturing facilities. The company granted stock options to employees under its 2021 plan, reflecting confidence in future growth.
Important Points:
-
Consolidated revenue for Q2 FY2026 stood at ₹11.21 billion, up 7.3% YoY.
-
Net profit grew 17.7% YoY to ₹694.7 million, marking strong bottom-line expansion.
-
EBITDA rose by 8.9% to ₹1.35 billion, with EBITDA margin improvement to 12.09%.
-
Specialty chemicals and nutrition products segments remain key growth drivers.
-
Focus on cost optimization and renewable energy adoption continues to enhance operational efficiency.
The company approved stock options under its employee incentive plan, signaling confidence in sustainability.
Source: Jubilant Ingrevia official results, ScanX Trade, CNBC TV18